Greedy Pigs Get Slaughtered
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The company is done for. RIP Affymax
I believe the Cyprus bailout news killed any run that HZNP would of had today.
GLUU keeps running!
That's assuming little to no revenues. Last year they expected $90 mil+ in revenues from Rayos.
DEERFIELD, IL--(Marketwire - Feb 11, 2013) - Horizon Pharma, Inc. ( NASDAQ : HZNP ) today announced preliminary (unaudited) revenues for the fourth quarter and fiscal year ended December 31, 2012.
Full year 2012 preliminary gross and net revenues were $23.0 million and $19.6 million, respectively.
DUEXIS® full year 2012 preliminary gross and net revenues were $13.2 million and $11.0 million, respectively.
Fourth quarter preliminary gross and net revenues were $8.2 million and $6.7 million, respectively.
DUEXIS fourth quarter preliminary gross and net revenues were $7.1 million and $6.0 million, respectively.
New prescriptions for DUEXIS increased 57% in the fourth quarter of 2012 to 31,130 versus 19,874 in the third quarter of 2012. New prescriptions for DUEXIS were 10,754 in December 2012.
Total prescriptions for DUEXIS increased 56% in the fourth quarter of 2012 to 39,060 versus 25,054 in the third quarter of 2012. Total prescriptions for DUEXIS were 13,969 in December 2012.
The Company had cash and cash equivalents of $104.1 million at December 31, 2012.
During the fourth quarter, the Company changed from recognizing revenue upon product being dispensed through patient prescriptions to recognizing revenue when product is sold into the wholesale and pharmacy channel. Based on approximately one year of minimal product return quantities and an enhanced ability and historical experience upon which to monitor DUEXIS inventory levels in the distribution channel and to assess the relative risk of potential product returns, the Company believes it now has the ability to reliably estimate returns and has begun recognizing revenue on the sale of DUEXIS at the point of sale to the wholesaler. This change in timing of revenue recognition resulted in a preliminary one-time increase to DUEXIS revenue of $1.8 million gross and $1.4 million net and is reflected in the fourth quarter and full year results presented.
Full RAYOS Commercial Launch Underway
Horizon also announced today it has initiated the full commercial launch of RAYOS® (prednisone) delayed-release tablets to rheumatologists and high-value primary care physicians through its full 150-person sales force. As previously announced, Horizon's commercial effort for RAYOS will focus on rheumatology indications, including rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR), which collectively comprise approximately three million patients in the U.S. The Company's sales representatives will promote RAYOS to approximately 3,500 rheumatologists in the U.S., who write over ninety-five percent of rheumatologist RA and PMR prescriptions.
In addition, the Company announced the approval of LODOTRA in South Korea in January, which triggered a milestone payment from its partner MundiPharma. The South Korean approval marks the 20th country in which LODOTRA is approved outside of the United States.
"Preliminary results were promising in the fourth quarter, with total fourth quarter DUEXIS prescriptions growing 56% versus the third quarter of 2012," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "In addition, feedback from the initial launch of RAYOS has been positive as we saw over 100 rheumatologists prescribe RAYOS during our targeted launch in December last year. This gives us confidence moving forward as we have now implemented the full commercial launch of RAYOS through our 150-person sales force."
How can it be bad?
GLUU!
(P) Pandora on short watch.
HZNP, By Monday, everyone is going to want in!
MUX and NG ripping it!
Loaded up on NG below $4 for a swing trade.
911 trade, must mean it's on fire
Buying HZNP for earnings on March 18, 2013
Any idea when this one will stop going down?
Anyone ever wonder why the penny stock market starts to boom during the first few months of the new year? This is the time of the year that many receive their tax returns, many penny trader are the most active because of this.
Many gold stocks in oversold territory. Might be a good time to check them out imo.
What's going on in the penny world?
Gold Stock Watchlist:
GLD
MUX
NG
ABX
Many more out there
This may be evidence of a problem with Fresenius and not Affymax. Fresenius has had problems in the past with deaths due to dialysis.
Through the years, dialysis has saved countless lives. Kidneys are necessary to keep the body functioning well, but some patients eventually develop renal failure. Dialysis machines partially replace the function of these machines and allow patients to survive until they can receive a transplant. Because the kidneys performs so many functions, a cocktail of drugs are necessary.
One important function of the kidneys is to filter acids, and two products from Fresenius Medical Care have been linked to sudden cardiac arrest in patients. Because of their alleged mishandling of information showing evidence of risk, Fresenius is now under fire and is likely to face a number of lawsuits in the coming years.
The trouble for Fresenius results from the fact that they appeared to be concerned about their products but did not take appropriate steps according to some analysts. An internal memo from Fresenius seemingly shows that members of the company were aware of potential problems but did not alert doctors appropriately. Because of this, many doctors prescribed dangerously high doses of GranuFlo and NaturaLyte that may have put patients at risk.
With sufficiently high doses of GranuFlo and NaturaLyte, patients are likely to experience a buildup of bicarbonate in patients’ blood. These high levels have been linked to heart arrhythmias and sudden cardiac arrest in many cases. Studies have conclusively linked the use of GranuFlo and NaturaLyte to a significantly increase rate of death for patiently undergoing dialysis treatments.
The FDA recalled both of these products in late June of 2012 after releasing a series of advisories upon receiving the Fresenius memo. Their quick action has lead many legal experts to speculate that significant lawsuits will shortly come as patients learn that their doctors were not given the information necessary to make the right decisions for their dialysis treatments.
Checking out oversold Gold and gold miners stocks. Could be a chance to make some big bucks.
when it was about to, you were screaming SCAM
I can see it, they both come around the same time. Btw, could "they" be the massive flipper with the etrade account holding this down?
Now your starting to sound like Dr. Seuss
Notice all the shares sold at .0003, they are just being piled on at .0004 after being bought at .0003. typical flippers holding this down.
The bashers are flippin this thing, lets make them chase...
sorry, I need to see some proof and not just your opinion. I'm in the penny market for the momo's, not in for long term investments. I know the risks involved and so do the majority of the people trading the penny markets.
VGPR #1 on breakout boards!
your such a saint for your good deed. How do you know?
yes, it means to get ready to call the fire department, because the stock is gonna be on fire!
Looks like we still have a bunch of naysayers on this board...
ENTID .0006's!!!
Just ignore, anyone can post lies on these boards.
flippers want those .0002's soooooo bad
WRONG! we close .0004!
well said
I wish it was that simple. what if the market really likes something but it doesn't go up??
I have first dibbs on .0002's, so keep on bashing mods and others hehehehehe...
last chance...
I agree, today looked like a lot of covering towards eod. I saw some mm scare tactics on the L2, trying to get people to sell so they can cover cheap.